NEW YORK (GenomeWeb News) – XDx today announced a deal with Laboratory Corporation of America to develop and commercialize a diagnostic test for systemic lupus erythematosus (SLE).
The two firms will work together in the discovery phase while LabCorp will develop and commercialize a test to predict flares of lupus. The collaboration pairs XDx's autoimmune diagnostics research and discovery expertise as well as SLE blood sample database with LabCorp's diagnostic development and commercialization resources, they said.
Financial and other terms of the deal were not disclosed.
Pierre Cassigneul, president and CEO of Brisbane, Calif.-based XDx, said the deal builds on the success of the company's AlloMap gene expression test for monitoring heart transplant rejection, and the firm is now concentrating on expanding its pipeline to include diagnostic tests directed at the immune system.
Mark Brecher, chief medical officer for LabCorp, added, "This agreement with XDx advances our strategy of developing and introducing tests to provide personalized information that can be used to help physicians and their patients."